4,667 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by SG Americas Securities LLC

SG Americas Securities LLC bought a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS) in the third quarter, HoldingsChannel.com reports. The institutional investor bought 4,667 shares of the company’s stock, valued at approximately $198,000.

Other large investors have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in GeneDx during the 2nd quarter worth about $34,000. nVerses Capital LLC bought a new position in shares of GeneDx in the 2nd quarter valued at about $50,000. Thompson Davis & CO. Inc. grew its holdings in shares of GeneDx by 20.8% in the 1st quarter. Thompson Davis & CO. Inc. now owns 24,094 shares of the company’s stock valued at $220,000 after acquiring an additional 4,150 shares in the last quarter. The Manufacturers Life Insurance Company bought a new position in shares of GeneDx in the 2nd quarter valued at about $290,000. Finally, Algert Global LLC bought a new position in shares of GeneDx in the 2nd quarter valued at about $356,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Trading Down 0.7 %

GeneDx stock opened at $57.79 on Wednesday. GeneDx Holdings Corp. has a 52 week low of $1.16 and a 52 week high of $61.96. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.22 and a current ratio of 2.38. The stock has a market capitalization of $1.51 billion, a P/E ratio of -11.16 and a beta of 2.32. The stock has a 50-day simple moving average of $41.34 and a 200 day simple moving average of $29.89.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.15. The business had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $58.90 million. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. Analysts expect that GeneDx Holdings Corp. will post -0.75 earnings per share for the current year.

Insiders Place Their Bets

In other GeneDx news, CFO Kevin Feeley sold 895 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $33.33, for a total transaction of $29,830.35. Following the completion of the sale, the chief financial officer now directly owns 39,910 shares in the company, valued at $1,330,200.30. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, major shareholder Opko Health, Inc. sold 60,000 shares of GeneDx stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $33.85, for a total value of $2,031,000.00. Following the completion of the sale, the insider now directly owns 3,123,403 shares in the company, valued at approximately $105,727,191.55. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Kevin Feeley sold 895 shares of GeneDx stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $33.33, for a total transaction of $29,830.35. Following the completion of the sale, the chief financial officer now owns 39,910 shares of the company’s stock, valued at approximately $1,330,200.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 468,668 shares of company stock worth $15,575,988 over the last three months. Insiders own 28.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on WGS shares. The Goldman Sachs Group raised their price objective on GeneDx from $32.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, October 16th. TD Cowen raised their price objective on GeneDx from $46.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Craig Hallum raised their price objective on GeneDx from $43.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. BTIG Research raised their price objective on GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Finally, Wells Fargo & Company assumed coverage on GeneDx in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $34.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus target price of $41.67.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.